Reports

426 Results (Page 1 of 18)

France Markets Research Reports

Rare Diseases

France Cystic Fibrosis (CF) Therapeutics Market Analysis

France Cystic Fibrosis (CF) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Cystic fibrosis (abbreviated CF) is a genetic disorder that causes mucus to build up in certain organs of the body, particularly the lungs and pancreas, resulting in breathing problems, respiratory infections and faulty digestion. The increasing prevalence of Cystic Fibrosis (CF) coupled with the rising treatment rate is one of the key factors anticipated to propel the demand for cystic fibrosis therapeutics over the forecast period. The key players are consistently involved in the development of new or combination of products to treat cystic fibrosis. Investment in the R&D is one of the strategic measures to beat the competition. The key players in this market are AbbVie Inc.; F. Hoffmann-La Roche Ltd; Gilead; Novartis AG; Vertex Pharmaceuticals Inc.; AIT (Advanced Inhalation Therapies); Alaxia; Teva Pharmaceutical Industries Ltd; Merck & Co. Inc.; Alcresta Therapeutics Inc.; Allergan; and AstraZeneca.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Apr, 2024 | PRICE: $3999

Pharmaceuticals

France Castrate Resistant Prostate Cancer Therapeutics Market Analysis

France Castrate Resistant Prostate Cancer Therapeutics Market valued at $281 Mn in 2022, projected to reach $450 Mn by 2030 with a 6.10% CAGR. The key drivers of the castration-resistant prostate cancer (CRPC) therapeutics market in France include the growing prevalence of prostate cancer among an aging population, enhanced awareness, and improved screening methods, as well as the French government's increasing healthcare expenditure. The France Castrate Resistant Prostate Cancer Therapeutics Market encompasses various players across different segments, including Sanofi, Pfizer, Johnson & Johnson, Roche, Bayer, Astellas, Amgen, Ipsen, AstraZeneca, Bristol-Myers Squibb, etc, among various others.

PUBLISHED: Apr, 2024 | FORMAT: PPT | LAST UPDATED: Apr, 2024 | PRICE: $3999

Pharmaceuticals

France Alzheimer’s Therapeutics Market Analysis

France alzheimer’s therapeutics market valued at $132 Mn in 2022, projected to reach $246 Mn by 2030 with a 8.1% CAGR. One of the key reasons driving the market's expansion for the growing demand for medicines used in Alzheimer's treatment is due to the disease's rising incidence among the elderly population. Top leading pharmaceutical companies presently operating in the market are Eisai, Pfizer, Janssen, Novartis, Biogen, Roche, Lundbeck, Otsuka Pharmaceutical, Teva Pharmaceutical and Sun Pharmaceutical.

PUBLISHED: Mar, 2024 | FORMAT: PPT | LAST UPDATED: Apr, 2024 | PRICE: $3999

Pharmaceuticals

France Infectious Disease Drugs Market Analysis

France Infectious Disease Drugs Market valued at $3.26 Bn in 2023, projected to reach $4.09 Bn by 2030 with a 3.27% CAGR. The market is driven by partnerships and collaborative research, awareness and education, and the aging population. The market is dominated by key players like Institut Merieux, AbbVie Inc., Gilead Sciences, GlaxoSmithKline plc, Merck & Co., F. Hoffman-La Roche Ltd., Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Novartis AG, and Sanofi S.A.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Mar, 2024 | PRICE: $3999

Pharmaceuticals

France Atopic Dermatitis Therapeutics Market Analysis

The France Atopic Dermatitis Therapeutics Market was valued at US $388 Mn in 2022, and is predicted to grow at (CAGR) of 7.80% from 2023 to 2030, to US $617 Mn by 2030. The key drivers of this industry include the upward trend in prevalence of Atopic Dermatitis (AD), emerging innovative therapeutics, and improved reimbursement policies. The industry is primarily dominated by players such as Sanofi, AbbVie, Viatris, Almirall, Leo Pharma, and Eli Lilly among others

PUBLISHED: Mar, 2024 | FORMAT: PPT | LAST UPDATED: Mar, 2024 | PRICE: $3999

Pharmaceuticals

France Atherosclerosis Therapeutics Market Report 2022 to 2030

France Atherosclerosis Therapeutics Market was valued at $77 Mn in 2022 and is estimated to reach $111 Mn in 2030, exhibiting a CAGR of 4.7% during the forecast period. The market for atherosclerosis therapeutics is expected to grow as a result of the rising incidence of cardiovascular diseases, which are exacerbated by sedentary lifestyles, poor eating habits, and an aging population worldwide. The market is currently dominated by leading pharmaceutical companies, including Sanofi, Novartis, Pfizer, Bayer, AstraZeneca, Merck Sharp & Dohme, AbbVie, Roche, Johnson & Johnson and Bristol-Myers Squibb.

PUBLISHED: Mar, 2024 | FORMAT: PPT | LAST UPDATED: Mar, 2024 | PRICE: $3999

Pharmaceuticals

France HIV Drugs Market Analysis

France HIV Drugs Market is at around $0.87 Bn in 2023 and is projected to reach $1.04 Bn in 2030, exhibiting a CAGR of 2.6% during the forecast period. The market is being influenced by factors such as increased HIV incidence, government initiatives, and technological improvements. The market is dominated by key players like Gilead Sciences, ViiV Healthcare, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., F. Hoffman-La Roche Ltd, Mylan, and Cipla.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

France Antifungal Drugs Market Analysis

France Antifungal Drugs Market is at around $0.43 Bn in 2023 and is projected to reach $0.53 Bn in 2030, exhibiting a CAGR of 2.8% during the forecast period. The market is expanding due to factors such as rising awareness and education, advancements in healthcare infrastructure, and an increase in the incidence of fungal infections. The market is dominated by key players like Pfizer Inc., Abbott Laboratories, Merck & Co., Inc., Astellas Pharma Inc., GlaxoSmithKline plc, Bayer AG, Novartis AG, Glenmark Pharmaceuticals Limited, Sanofi S.A., and Gilead Sciences Inc.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

France Asthma and COPD Therapeutics Market Analysis

The France Asthma and COPD Therapeutics Market was valued at US $0.92 Bn in 2022, and is predicted to grow at (CAGR) of 4.20% from 2023 to 2030, to US $1.28 Bn by 2030. The key drivers of this industry include the rise in the prevalence of COPD and asthma, unmet medical needs, technological advancements, and others. The industry is primarily dominated by players such as, GlaxoSmithKline, Tetherex, Novartis, Sulfateq, Verona, and Boehringer Ingelheim, among others.

PUBLISHED: Feb, 2024 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

France Wearable Injectors Market Analysis

France Wearable Injectors Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Wearable Injectors market is growing globally due to the strong healthcare infrastructure, rise in the incidence of lifestyle disorders, an ageing population that is more susceptible to diseases, increase in the desire for minimally invasive (MI) treatment alternatives, rise in chronic diseases like diabetes, autoimmune diseases, patient preference for self-administration medications in the comfort of their homes which enhances patient convenience, improves medication adherence, technological advancements in wearable injector technology which have improved device usability, functionality, patient experience. Continuous drug delivery provided by wearable injectors like more stable drug levels, reduced fluctuations, focus on patient centric care and cost-effective solutions provided by wearable injectors. Medtronic plc, Insulet Corporation, West Pharmaceutical Services, Inc., Enable Injections, SteadyMed Therapeutics, Inc., Sensile Medical AG, CeQur SA, Ypsomed AG, Becton, Dickinson and Company and Tandem Diabetes Care, Inc. are the key global market players in wearable injectors market.

PUBLISHED: Feb, 2024 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

France Alopecia Drugs (Hair Loss) Market Analysis

France alopecia drugs (hair loss) market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The rising prevalence of alopecia, rising awareness and consciousness among individuals about their appearance, and the development of advanced treatment technologies. Johnson & Johnson, Merck & Co., GlaxoSmithKline plc, Cipla Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Pfizer Inc., Histogen Inc., Aclaris Therapeutics, and Concert Pharmaceuticals are the key players in this market.

PUBLISHED: Feb, 2024 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

France Aminoglycosides Market Analysis

France Aminoglycosides Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The Aminoglycosides market is a segment of the pharmaceutical industry that focuses on the production and sale of aminoglycoside antibiotics. Key factors driving the market include the increasing prevalence of bacterial infections, especially drug-resistant strains, which require potent antibiotics like aminoglycosides. The growing geriatric population and the rise in chronic diseases also contribute to the demand for aminoglycosides. The market analysis also considers restraints such as the potential side effects and toxicity associated with aminoglycoside use. These antibiotics can cause serious adverse effects, including kidney damage and hearing loss, which limit their long-term use. Furthermore, the emergence of alternative antibiotics and the growing concern over antibiotic resistance pose challenges to the market growth. Some of the prominent global players in the Aminoglycosides market include Pfizer Inc., Merck & Co., Inc., Novartis AG, Bristol Myers Squibb Company, Eli Lilly and Company, Abbott Laboratories, Johnson & Johnson, Aurobindo Pharma Ltd., Teva Pharmaceutical Industries Ltd., and Mylan N.V.

PUBLISHED: Feb, 2024 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

France Anti-Aging Drugs Market Analysis

France Anti-Aging Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The Anti-Aging Drugs market is driven by the increasing aging population, advancements in medical research, growing consumer awareness and beauty standards, and the emphasis on preventive healthcare, prompting individuals to seek effective solutions for maintaining a youthful appearance and improving overall well-being. However, the Anti-Aging Drugs market also faces certain restraints. These include stringent regulatory requirements, potential safety concerns, and ethical considerations associated with the use of anti-aging drugs. Additionally, the high cost of some anti-aging drugs may limit their accessibility to a wider population. The Anti-Aging Drugs market is highly competitive, with several key players contributing to its growth and development. Companies such as Allergan, Galderma, Merz Pharma, and Johnson & Johnson are renowned for their expertise in developing and manufacturing anti-aging drugs and treatments.

PUBLISHED: Feb, 2024 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

France Anti-Venom Market Analysis

France Anti-Venom Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Purified antibodies are used to prevent snake venom from attaching to tissues and causing severe allergic reactions, blood clotting, muscular injury, or nervous system difficulties. The anti-venom market is being driven by the rising global incidence of snakebites, which is fueling demand for effective snakebite treatment options such as anti-venom products. Anti-venom awareness and education efforts have been critical in emphasising the necessity of anti-venom in snakebite management. Manufacturing and delivery techniques advancements have enhanced the safety, efficacy, and accessibility of anti-venom medications. However, market obstacles include restricted access in rural places, high manufacturing costs, a lack of specificity and efficacy in particular formulations, and safety concerns about potential adverse responses and difficulties during therapy.Some global players in the anti-venom market include CSL Limited, BTG plc, Merck & Co., Inc., Pfizer Inc., Sanofi Pasteur SA, Haffkine Bio-Pharmaceutical Corporation Ltd., Rare Disease Therapeutics, Inc., Instituto Bioclon, S.A. de C.V., and Bharat Serums and Vaccines Limited.

PUBLISHED: Feb, 2024 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

France Anticoagulants Market Analysis

France Anticoagulants Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Anticoagulants, commonly known as blood thinners, reduce the risk of blood clots and related consequences by suppressing the clotting mechanisms in the blood. Increased cardiovascular illnesses, an ageing population, greater awareness, technical improvements, advantageous reimbursement policies, and an increase in surgical operations are driving the anticoagulants market. However, there are hazards of bleeding, regulatory requirements, and generic alternatives. The presence of many prominent companies who play a crucial part in developing the industry characterises the global anticoagulants market. Pfizer Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Bayer AG, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company, Limited, Sanofi S.A., Novartis AG, Merck & Co., Inc., and Portola Pharmaceuticals, Inc. are among the prominent participants.

PUBLISHED: Feb, 2024 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

France Antiepileptics Drugs Market Analysis

France Antiepileptics Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Epilepsy is a chronic neurological disorder characterized by recurrent seizures. The market for antiepileptic drugs is driven by the growing prevalence of epilepsy worldwide and the continuous need for effective and well-tolerated medications. Continuous advances in drug research and development help to bring new and improved antiepileptic treatments to market. These developments result in the creation of pharmaceuticals with improved efficacy, safety profiles, and fewer side effects, which drives market expansion. Some prominent players in the market include UCB Pharma, GlaxoSmithKline plc, Pfizer Inc., Novartis AG, Johnson & Johnson, Sanofi S.A., Eisai Co., Ltd., Sunovion Pharmaceuticals Inc., Cephalon, Inc., and Teva Pharmaceutical Industries Ltd.

PUBLISHED: Feb, 2024 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

France Antithrombotic Drugs Market Analysis

France Antithrombotic Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The rising prevalence of cardiovascular disorders, growing geriatric population, developments in medication research, supportive government initiatives and advantageous reimbursement regulations for antithrombotic drugs drive market expansion. The antithrombotic drugs market is dominated by several key players who play a crucial role in driving advancements in the field of cardiovascular medicine. These key players include renowned pharmaceutical companies such as Pfizer Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Sanofi S.A., Eli Lilly and Company, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Portola Pharmaceuticals, Inc., AstraZeneca PLC, and Bayer AG.

PUBLISHED: Feb, 2024 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

France Asthma Drugs Market Analysis

France Asthma Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The market for asthma drugs is primarily driven by the increasing prevalence of asthma globally, Growing awareness among patients and healthcare providers about the importance of asthma management and the availability of effective treatment options further fuel market growth. Key players in the asthma drugs market include pharmaceutical companies such as GlaxoSmithKline, Roche, AstraZeneca, Novartis, Merck & Co., and Teva Pharmaceutical Industries.

PUBLISHED: Feb, 2024 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

France Atherosclerosis Drugs Market Analysis

France Atherosclerosis Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The atherosclerosis drugs market is driven by factors such as the rising prevalence of cardiovascular diseases, advancements in drug development, and growing awareness about early diagnosis and treatment. The key players in the atherosclerosis drugs market include Pfizer Inc., AstraZeneca PLC, Novartis AG, Bristol-Myers Squibb Company, Sanofi S.A., Merck & Co., Inc., Amgen Inc., Eli Lilly and Company, Bayer AG, and GlaxoSmithKline PLC.

PUBLISHED: Feb, 2024 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

France Atopic Dermatitis Drugs Market Analysis

France Atopic Dermatitis Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The market for atopic dermatitis drugs is driven by the increasing prevalence of the condition, especially among children, leading to a demand for effective treatments. Some of the prominent players in the market include Pfizer Inc., Sanofi SA, Novartis AG, Regeneron Pharmaceuticals Inc., Galderma S.A., Leo Pharma A/S, AbbVie Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, and Johnson & Johnson.

PUBLISHED: Feb, 2024 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

France Autologous Matrix-induced Chondrogenesis Market Analysis

France Autologous Matrix-induced Chondrogenesis Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The AMIC market is driven by increasing knee injuries and cartilage defects, advancements in regenerative medicine, and the growing geriatric population. However, limited awareness and high costs are restraints. Ongoing research, collaborations, and investments are expected to address restraints and drive further advancements in the AMIC market. Key players globally in AMIC market are Geistlich Pharma AG, Arthrex, Zimmer Biomet Holdings, Smith & Nephew plc, Vericel Corporation, and B. Braun Melsungen AG, among others.

PUBLISHED: Feb, 2024 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

France Axial Spondyloarthritis (axSpA) Market Analysis

France Axial Spondyloarthritis (axSpA) Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. With ongoing research and development efforts, the expansion of treatment options, and increasing patient awareness, the axSpA market is expected to witness significant growth in the coming years. AbbVie Inc., Amgen Inc., Johnson & Johnson, Novartis International AG, Pfizer Inc., Eli Lilly and Company, Merck & Co., UCB S.A., Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH are the global key players in axSpA market.

PUBLISHED: Feb, 2024 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

France Biological Safety Testing Market Analysis

France Biological safety testing Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The biological safety testing market is driven by increasing demand for biologics, stringent regulatory requirements, rising incidence of infectious diseases, technological advancements, and growth in the biotechnology and pharmaceutical industries. Charles River Laboratories International, Merck KGaA, Lonza Group Ltd., Eurofins Scientific, SGS SA, WuXi AppTec, Toxikon Corporation, Avista Pharma Solutions, Nelson Laboratories, Pace Analytical Services are among the global key players.

PUBLISHED: Feb, 2024 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

France Biosimilar Monoclonal Antibodies Market Analysis

France Biosimilar Monoclonal Antibodies Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Market drivers for biosimilar monoclonal antibodies include rising demand for low-cost biologics, the increasing frequency of chronic diseases, and the need for more economical biologic therapeutics. Among the key global pharmaceutical companies in the Biosimilar Monoclonal Antibodies Market are Samsung Bioepis Co., Celltrion Inc., Biocon Ltd., Pfizer Inc., Amgen Inc., Novartis AG (Sandoz), Mylan N.V., Boehringer Ingelheim International GmbH, Fresenius Kabi AG, and Teva Pharmaceutical Industries Ltd.

PUBLISHED: Feb, 2024 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

France Biosimilars Market Analysis

France Biosimilars Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Cost-effectiveness, patent expirations of reference biologics, increasing demand for biologic medicines, a supportive regulatory environment, and increased acceptance by healthcare professionals are all main drivers in the biosimilars market. Novartis AG, Pfizer Inc., Amgen Inc., Coherus Biosciences Inc., Mylan NV (Viatris Inc.), and Samsung Bioepis Co., Ltd. are among the top competitors in the studied market.

PUBLISHED: Feb, 2024 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

subscribe to our newsletter
up